IDEAYA Biosciences, Inc. (IDYA)
$36.06-0.14%Close
SELLBEAR · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3.4B
- Beta
- -0.09
- P/E (TTM)
- -19.08
- Short % float
- 10.55%
- Days to cover
- 8.4
- SI change
- -7.5%
- 1W
- -5.25%
- 1M
- -4.07%
- vs SPY 1W
- -5.68%
- vs SPY 1M
- -6.13%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDSELLRevolution Medicines, Inc.$40.3BRECOVERYQ 30$189.76+2.21%
- ERASSELLErasca, Inc.$5.6BRECOVERYQ 4$16.03-3.56%
- COGTSELLCogent Biosciences, Inc.$5.3BRECOVERYQ 12$31.00-3.94%
- TNGXSELLTango Therapeutics, Inc.$3.9BRECOVERYQ 24$23.81+1.51%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 11$22.35-0.85%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38-1.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on IDYA?
- LOPJLB’s latest quantitative signal on IDEAYA Biosciences, Inc. (IDYA) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is IDYA in?
- IDEAYA Biosciences, Inc. (IDYA) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does IDEAYA Biosciences, Inc. (IDYA) do?
- IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosy…